KPC(600422) 华福证券·2025-03-18 07:35Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [6][22]. Core Insights - The company achieved a revenue of 8.4 billion yuan in 2024, reflecting a 9.1% increase compared to the previous year, while the net profit attributable to shareholders reached 650 million yuan, marking a 45.7% increase [2][3]. - The acquisition of a 51% stake in China Resources Shenghuo is expected to enhance the company's operational capabilities and market position, contributing to historical highs in net profit and net profit after deducting non-recurring items [3][6]. - The company is focusing on developing strong single products and nurturing high-growth potential products, leveraging the resources and capabilities of China Resources [5][6]. Financial Performance Summary - In 2024, the company reported a revenue of 8.4 billion yuan, with a net profit of 650 million yuan, and a net profit after deducting non-recurring items of 420 million yuan, showing a year-on-year growth of 25.1% [2][4]. - The revenue forecast for 2025, 2026, and 2027 is projected to be 9.3 billion yuan, 10.3 billion yuan, and 11.5 billion yuan respectively, with growth rates of 11% for each year [6][12]. - The net profit for the same years is expected to be 760 million yuan, 910 million yuan, and 1.07 billion yuan, with growth rates of 17%, 20%, and 17% respectively [6][12]. Product Performance - Oral dosage products generated revenue of 3.69 billion yuan, showing a slight increase of 1.2%, while injection products faced a significant decline in revenue by 49.1% to 540 million yuan due to policy impacts [4][5]. - Key products include the injection of Xue Saitong, which saw a 54.7% drop in sales, while Tianma injection liquid experienced a 12.9% increase in sales [4][5].